Eton Pharmaceuticals is initiating a new development program, ET-900, for infantile and epileptic spasms using mecasermin, an active ingredient in their existing product. This involves licensing patent rights and submitting an IND for a Phase 2 trial, indicating a potential new revenue stream but with a long development timeline.
Eton Pharmaceuticals has announced the initiation of ET-900, a new development program to evaluate mecasermin for infantile and epileptic spasms. This is a significant step for the company as it involves licensing new patent rights from Baylor College of Medicine and submitting a research IND for a Phase 2 clinical trial, targeting enrollment in Q1 2027. While mecasermin is the active ingredient in their marketed product INCRELEX, its efficacy for spasms is unestablished, making this a high-risk, high-reward venture. For traders, this presents a long-term opportunity for Eton if the trials are successful, potentially expanding their product's market, but short-term impact is limited due to the distant trial start and unproven efficacy.